Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| fibroblast | 9 studies | 27% ± 6% | |
| neuron | 7 studies | 43% ± 24% | |
| pericyte | 7 studies | 30% ± 13% | |
| smooth muscle cell | 6 studies | 22% ± 6% | |
| connective tissue cell | 5 studies | 27% ± 7% | |
| myofibroblast cell | 4 studies | 30% ± 5% | |
| retinal ganglion cell | 4 studies | 59% ± 26% | |
| amacrine cell | 4 studies | 39% ± 16% | |
| GABAergic neuron | 4 studies | 31% ± 8% | |
| glutamatergic neuron | 4 studies | 36% ± 14% | |
| astrocyte | 3 studies | 27% ± 4% | |
| retina horizontal cell | 3 studies | 31% ± 7% | |
| Mueller cell | 3 studies | 27% ± 7% | |
| oligodendrocyte | 3 studies | 25% ± 7% | |
| oligodendrocyte precursor cell | 3 studies | 25% ± 9% | |
| interneuron | 3 studies | 24% ± 9% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| brain | 100% | 3505.96 | 2641 / 2642 | 99% | 114.11 | 700 / 705 |
| prostate | 69% | 412.47 | 168 / 245 | 77% | 7.99 | 385 / 502 |
| ovary | 100% | 1162.52 | 180 / 180 | 36% | 3.45 | 154 / 430 |
| uterus | 98% | 1427.65 | 167 / 170 | 33% | 15.54 | 152 / 459 |
| breast | 67% | 395.94 | 307 / 459 | 51% | 4.69 | 568 / 1118 |
| bladder | 76% | 434.05 | 16 / 21 | 29% | 3.74 | 144 / 504 |
| intestine | 72% | 600.94 | 695 / 966 | 30% | 3.09 | 157 / 527 |
| blood vessel | 87% | 491.83 | 1159 / 1335 | 0% | 0 | 0 / 0 |
| adrenal gland | 20% | 144.24 | 52 / 258 | 67% | 170.48 | 153 / 230 |
| lung | 45% | 200.14 | 261 / 578 | 37% | 3.50 | 423 / 1155 |
| pancreas | 0% | 0 | 0 / 328 | 81% | 13.04 | 145 / 178 |
| esophagus | 56% | 298.36 | 808 / 1445 | 19% | 1.30 | 35 / 183 |
| stomach | 34% | 207.87 | 121 / 359 | 34% | 3.40 | 96 / 286 |
| kidney | 20% | 77.44 | 18 / 89 | 38% | 4.62 | 339 / 901 |
| thymus | 23% | 83.69 | 153 / 653 | 33% | 2.95 | 198 / 605 |
| heart | 49% | 256.16 | 421 / 861 | 0% | 0 | 0 / 0 |
| adipose | 45% | 204.06 | 543 / 1204 | 0% | 0 | 0 / 0 |
| skin | 24% | 147.36 | 441 / 1809 | 6% | 1.87 | 30 / 472 |
| spleen | 17% | 66.97 | 40 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 7% | 0.63 | 3 / 45 |
| muscle | 6% | 37.03 | 52 / 803 | 0% | 0 | 0 / 0 |
| liver | 0% | 1.16 | 1 / 226 | 5% | 0.28 | 19 / 406 |
| eye | 0% | 0 | 0 / 0 | 3% | 0.41 | 2 / 80 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| peripheral blood | 0% | 0 | 0 / 929 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0032088 | Biological process | negative regulation of NF-kappaB transcription factor activity |
| GO_0045892 | Biological process | negative regulation of DNA-templated transcription |
| GO_0005654 | Cellular component | nucleoplasm |
| GO_0005634 | Cellular component | nucleus |
| Gene name | TCEAL7 |
| Protein name | Transcription elongation factor A protein-like 7 (TCEA-like protein 7) (Transcription elongation factor S-II protein-like 7) |
| Synonyms | |
| Description | FUNCTION: Plays a role in the negative regulation of NF-kappa-B signaling at the basal level by modulating transcriptional activity of NF-kappa-B on its target gene promoters. Associates with cyclin D1 promoter containing Myc E-box sequence and transcriptionally represses cyclin D1 expression. Regulates telomerase reverse transcriptase expression and telomerase activity in both ALT (alternative lengthening of telomeres)and telomerase-positive cell lines. . |
| Accessions | Q9BRU2 ENST00000372666.1 ENST00000332431.5 |